In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Finding Solutions For COVID Vaccine Distribution In Africa’s ‘Last Mile’

Executive Summary

More COVID-19 vaccines are beginning to flow into Africa, as coordination between partner organizations and African governmental agencies improves. However, gaps remain in cold chain storage, information flow on the ground is lagging and vaccine hesitancy persists. Also, pandemic-related economic depression in some African countries is jeopardizing procurement and access to vaccines. 

You may also be interested in...



Moderna Makes Case For Sustainable Vaccine Manufacturing In Africa

Less than 4% of the population in Africa has been immunized against COVID-19 and in some quarters the finger of blame has been pointed at the pharma industry. Believing the situation requires a long-term strategy, Moderna is going to build a plant on the continent with the goal of producing up to 500 million doses of vaccines each year.

Optimism About Alzheimer’s Disease: Gene Therapy, Digital Therapeutics And New Biomarkers

Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.   

Building Targeted Chemotherapies: ADCs, ProTides And ‘Click Chemistry’

If targeted therapies for cancer represent a more precise, laser-like attack on solid tumors and blood cancers, cytotoxic chemotherapies are more like a ham-fisted boxer punching every cell in sight. New methods for delivering chemotherapy directly into cancer cells may help to improve efficacy and reduce – or eliminate – damaging and sometimes deadly side effects.    

Topics

UsernamePublicRestriction

Register

IV124886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel